Your session is about to expire
← Back to Search
PD-1/PD-L1 Inhibitor Therapy Duration for Cancer
Study Summary
This trial will study whether it is better to stop treatment with PD-1/PD-L1 therapy after one year or continue until disease progression.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am being treated with a PD-1/PD-L1 inhibitor for my advanced solid tumor cancer.My latest scans show my disease hasn’t worsened in the past 6 weeks.Patients can have either detectable or undetectable disease according to a specific set of guidelines.I agreed to possibly stop or continue immunotherapy after 1 year.My doctor stopped my immune therapy due to side effects.I started treatment with a PD-1/PD-L1 inhibitor and another drug.You have shown signs that your disease is getting worse before starting the trial.
- Group 1: Discontinue Treatment with PD-1/PD-L1-1 inhibitor
- Group 2: Continue Treatment with PD-1/PD-L1 inhibitor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What disease does Discontinue PD-1/PD-L1-1 inhibitor help patients with the most?
"Discontinue PD-1/PD-L1-1 inhibitor is an effective treatment for various cancers, such as malignant neoplasms and unresectable melanoma."
Have patients participated in this type of treatment before?
"Discontinue PD-1/PD-L1-1 inhibitor has been the focus of medical research since 2008. The first study, sponsored by Hoffmann-La Roche, occurred that year and involved 720 participants. Following the success of this initial study, Discontinue PD-1/PD-L1-1 inhibitor received Phase 2 drug approval in 2009. As of 2021, there are 2081 active studies involving this medication taking place across 4025 cities in 78 countries."
Could you please elaborate on the potential risks of taking a PD-1/PD-L1-1 inhibitor?
"Discontinue PD-1/PD-L1-1 inhibitor's safety is supported by multiple rounds of clinical data, giving it a score of 3."
Share this study with friends
Copy Link
Messenger